# US 2019/0314516 A1 · Blood coagulation protein conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314516 A1
- Document ID: US20190314516A1
- Status: Published application
- Kind: A1
- Application number: 16/447,134
- Filed: 2019-06-20
- Published: 2019-10-17
- Earliest claimed: 2009-07-27
- Assignees: Baxalta Incorporated
- Applicants: Baxalta Incorporated; Baxalta GmbH
- Inventors: Juergen Siekmann; Stefan Haider; Hanspeter Rottensteiner; Peter Turecek
- Web page: https://patentgrep.com/patent/US20190314516A1

## CPC

- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61K 38/37: Factors VIII
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/24: of the sex hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 1/1075: {by covalent attachment of amino acids or peptide residues}
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C08B 37/0006: {Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid}
- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A modified blood coagulation protein comprising:
a) a blood coagulation protein having biological activity selected from the group consisting of Factor IX (FIX), Factor VIII (FVIII), Factor VIIa (FVIIa), Von Willebrand Factor (VWF), Factor FV (FV), Factor X (FX), Factor XI (FXI), Factor XII (FXII), thrombin (FII), protein C, protein S, tPA, PAI-1, tissue factor (TF) and ADAMTS 13 protease; and
b) at least one water soluble polymer selected from the group consisting of polysialic acid (PSA), polysaccharides, pullulan, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, starch, polyoxazoline, polyacryloylmorpholine, and polyphosphazene, and a linker bound to said blood coagulation protein of (a) at one or more carbohydrate moieties;
wherein the linker comprises 1-50 ethylene glycol units; and
wherein said modified blood coagulation protein has an oxime linkage between said one or more carbohydrate moieties and the linker on the water soluble polymer.

### Claim 24 (depends on 23)

The modified blood coagulation protein of claim 23, wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.

### Claim 25 (depends on 23)

The modified blood coagulation protein of claim 23, wherein said modified blood coagulation protein has a specific activity of at least 60% relative to an unmodified blood coagulation protein.

### Claim 26 (depends on 23)

The modified blood coagulation protein of claim 23, wherein said modified blood coagulation protein has a specific activity of at least 70% relative to an unmodified blood coagulation protein.

### Claim 27 (depends on 23)

The modified blood coagulation protein of claim 23, wherein said modified blood coagulation protein has Factor VIII (FVIII) biological activity.

### Claim 28 (depends on 23)

The modified blood coagulation protein of claim 23, wherein said modified blood coagulation protein has Factor IX (FIX) biological activity.

### Claim 29 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein is a full-length blood coagulation protein.

### Claim 30 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the oxidized carbohydrate moiety of the modified blood coagulation protein is located in the activation peptide of the blood coagulation protein.

### Claim 31 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the linker has 2 or 4 ethylene glycol units.

### Claim 32 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the water soluble polymer is PSA.

### Claim 33 (depends on 32)

The modified blood coagulation protein of claim 32, wherein the PSA is comprised of about 5-500 sialic acid units.

### Claim 34 (depends on 32)

The modified blood coagulation protein of claim 32, wherein the PSA is comprised of about 10-300 sialic acid units.

### Claim 35 (depends on 32)

The modified blood coagulation protein of claim 32, wherein the PSA has a molecular weight from 2,000 Da to 45,000 Da.

### Claim 36 (depends on 32)

The modified blood coagulation protein of claim 32, wherein the PSA has a molecular weight from 3,000 Da to 35,000 Da.

### Claim 37 (depends on 32)

The modified blood coagulation protein of claim 32, wherein the PSA has a molecular weight from 5,000 Da to 25,000 Da.

### Claim 38 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity and the linker comprises 1-50 ethylene glycol units.

### Claim 39 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity and the linker has 2 or 4 ethylene glycol units.

### Claim 40 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity and the linker has 2 or 4 ethylene glycol units.

### Claim 41 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units.

### Claim 42 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units.

### Claim 43 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.

### Claim 44 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FVIII biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.

### Claim 45 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity and the linker comprises 1-50 ethylene glycol units.

### Claim 46 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity and the linker has 2 or 4 ethylene glycol units.

### Claim 47 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity and the linker has 2 or 4 ethylene glycol units.

### Claim 48 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units.

### Claim 49 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units.

### Claim 50 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker comprises 1-50 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.

### Claim 51 (depends on 23)

The modified blood coagulation protein of claim 23, wherein the modified blood coagulation protein has FIX biological activity, the water soluble polymer is PSA having a molecular weight from 3,000 Da to 35,000 Da, and wherein the linker has 2 or 4 ethylene glycol units, and wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
